WATCH OUR COMPLIMENTARY GUIDE TO OPIOIDS – ALTERNATIVES AND PROVIDED SUPPORT
Welcome to the Mayo Clinic Opioid CME. I'm Dr. Helena Gazelka, and I chair the Mayo Clinic Opioid Stewardship Program, a role that I have enjoyed since its inception in 2016.
In the past five years, I have learned a tremendous amount about the opioid epidemic, its sources, and its potential solutions. My team and I have worked tirelessly, both inside Mayo Clinic and outside of it, in our own communities and states to combat the epidemic and to educate others, including providers and patients, about safe and appropriate use of opioid medications.
Our work at Mayo Clinic has garnered national attention, and I am pleased that our accomplishments and lessons learned have benefited other providers and practices. I am passionate about safe opioid use. These medications are some of the most valuable that we have discovered in the last centuries, and we must protect appropriate use of them for patients who rely upon them for their quality of life while protecting our society from the ravages of their abuse.
This opioid course is unique in that it showcases the expertise and experience of many experts, which combined encompasses a range of topics pertinent to opioid delivery and how to avoid using opioids when other means are available to manage pain.
GAIN A DEEPER UNDERSTANDING OF OPIOIDS YOU RELY ON IN YOUR DAY-TO-DAY AND EARN CME
The course will provide guidance on a diffuse range of topics related to opioids, including: opioid pharmacology, when and why to choose certain opioids, how to manage related side effects, how to manage patients while treating them with opioids, how to taper opioids, pearls for having difficult conversations with patients, interventional options for pain control, urine toxicology screening, legal implications of opioid prescribing, and how to approach and manage patients with opioid use disorder.
WATCH AND LEARN FROM THE LEADING EXPERTS IN THE FIELD:
James Watson, M.D., a neurologist at Mayo Clinic discusses how neuropathic pain adjuvants that are non-opioid based are underutilized, sharing tips for how to optimize first-line drug options and secondary options for refractory cases.
James C. Watson, MD, 40:38
Dr. Eleshia J. Morrison, a board-certified pain psychologist with additional Specialties in Oncology and transplantation discusses strategies for navigating difficult discussions about opioids.
Eleshia J. Morrison, PhD, LP, 40:06
Dr. Jacob J. Strand, a palliative medicine physician, discusses opioid pharmacology in patient care and how to identify the right drug for the right patient.
Jacob J. Strand, MD, 18:21
Dr. W. Michael Hooten, an anesthesiologist, identifies the key clinical elements of an opioid monitoring program by using the B-CAREFUL monitoring program.
W. Michael Hooten, MD, 21:42
Julie L. Cunningham, a pharmacologist in clinical practice, discusses chronic opioid tapering and pearls for the primary care provider, describing case-based tapering strategies.
Julie L. Cunningham, PharmD, RPh, 28:18
Molly Feely, MD, a palliative medicine physician at Mayo Clinic discusses the management of opioid-induced side effects. Dr. Feely covers opioid-induced constipation, nausea, sedation, pruritus, and hypogonadism.
Molly A. Feely, MD, 31:43
Tim Lamer, M.D., an anesthesiologist and pain management specialist at Mayo Clinic, discusses interventional options for treating chronic pain and how to evaluate the appropriateness of these treatments for patients.
Tim J. Lamer, MD, 13:56
Loralie Langman, director of the Clinical and Forensic Toxicology Laboratory and Clinical Mass Spec Laboratory at the Pharmacogenomics Laboratory at Mayo Clinic, Minnesota, talks about how to interpret urine drug tests, covering some of the drug tests that are typically ordered and how to understand some of the limitations of each of them.
Loralie J. Langman, PhD, 21:03
I hope that you not only learn from this group of lectures but that you also enjoy it and find it entertaining and interesting. Thank you for all that you do to care for your patients. We are excited to collaborate with you on this very important topic.